Proteins and Peptides

22 Feb 2018 Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide
22 Feb 2018 DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
21 Feb 2018 Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial
19 Feb 2018 sterna biologicals Reports Phase 2a Study Data Demonstrating Efficacy of Its GATA-3 Specific DNAzyme Formulation SB012 in Patients with Ulcerative Colitis
18 Feb 2018 Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
16 Feb 2018 Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
15 Feb 2018 IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
14 Feb 2018 Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
14 Feb 2018 Herantis Pharma opening recruitment in Parkinson's disease study in Helsinki and Lund based on favorable first CDNF safety assessment
13 Feb 2018 Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)
13 Feb 2018 Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
13 Feb 2018 Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
09 Feb 2018 Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B
09 Feb 2018 Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes
08 Feb 2018 Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
08 Feb 2018 BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018
08 Feb 2018 Sanofi announces new safety data for investigational avalglucosidase alfa in patients with Pompe disease
07 Feb 2018 Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
06 Feb 2018 Endo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of Cellulite
06 Feb 2018 Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study
01 Feb 2018 Ferring's ZOMACTON® (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Deficiency in Adults
01 Feb 2018 Partner Therapeutics (PTx) Acquires Leukine® from Sanofi
30 Jan 2018 Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label
29 Jan 2018 Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
29 Jan 2018 ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up